Endoscopic Retrograde Cholangiopancreatography
Recruiting
Observational Study
Gastro-Intestinal Disorder
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 15 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 100 (estimated)
- Sponsor
- Methodist Health System · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The risk of post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis(PEP) is influenced by patient and procedure-related factors. Strategies to decrease PEP(Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis) are of great importance.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Patients \>15 years Included in MDI's Registry Underwent ERCP between January 1, 2000 through December 31, 2025
Exclusion Criteria:
Patients \<15 years Patients in which cannulation was via a surgical anastomosis Patients in which cannulation was not attempted due to gastric o…
Contacts